Common causes of neuropathy such as diabetes ... used in conjunction with the other studies and the clinical presentation to suggest a diagnosis of CIDP. Once the diagnosis is secured, treatment with ...

for 6 months in 45 patients with CIDP. 41 The primary outcome, discontinuation due to any cause, was higher with methylprednisolone than IVIg (52% vs 13%; relative risk, 0.54; 95% CI, 0.34-0.87).

CIDP is often considered the chronic form of Guillain-Barré Syndrome and, as such, can be more problematic in that it lasts longer, causes more damage and is more difficult to recover from.

CIDP is a rare autoimmune neurological disorder that causes progressive muscle weakness and sensory loss due to damage to the peripheral nerves. The initial data readout, encompassing pooled data ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

In total, 1435 patients with CIDP and 4305 controls were included. Data revealed that the all-cause health care resource utilization (HCRU) for those with CIDP was more than 3 times the HCRU for ...

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase) is the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue ...

Today’s results show that deeper IgG reduction leads to deeper responses in MG and CIDP. Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction ...